FENC · Fennec Pharmaceuticals Inc. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-10-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-10-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-10-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-10-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-10-12 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Common Shares
|
2,326 |
| 2026-10-12 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Common Shares
|
3,846 |
| 2026-10-12 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Common Shares
|
2,224 |
| 2026-10-12 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Common shares
|
3,946 |
| 2026-10-12 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Common shares
|
3,846 |
| 2026-09-30 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-09-30 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-09-30 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-09-30 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-09-30 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-09-15 | Brughera Marco Maria |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Common Shares
|
15,545 |
| 2026-09-15 | Brughera Marco Maria |
Director |
Convert↑
Filing footnotes — Common Shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Common Shares
|
15,545 |
| 2026-09-15 | Brughera Marco Maria |
Director |
Convert↓
Filing footnotes — Stock Option (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Stock Option
|
15,545 |
| 2026-09-01 | Raykov Rosty |
Insider |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Common shares
|
10,000 |
| 2026-08-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-08-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-08-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-08-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents sale of previously vested restricted shares and vested performance shares. |
Common Shares
|
12,000 |
| 2026-08-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-08-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-08-31 | Raykov Rosty |
Insider |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-08-28 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |
Common shares
|
21,928 |
| 2026-08-28 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Convert↓
Filing footnotes — Stock Options (Direct)
Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |
Stock Options
|
21,928 |
| 2026-08-27 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person. |
Common shares
|
75,000 |
| 2026-08-03 | Raykov Rosty |
Insider |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Common shares
|
10,000 |
| 2026-07-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-07-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-07-31 | Raykov Rosty |
Insider |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-07-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-07-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-07-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-07-01 | Raykov Rosty |
Insider |
Convert↓
Filing footnotes — Stock Options (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Stock Options
|
15,597 |
| 2026-07-01 | Raykov Rosty |
Insider |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
15,597 |
| 2026-07-01 | Raykov Rosty |
Insider |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-07-01 | Raykov Rosty |
Insider |
Sell↓
Filing footnotes — Common shares (Direct)
Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
9,599 |
| 2026-06-30 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-06-30 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-06-30 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-06-30 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-06-30 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-06-10 | Islam Khalid |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
25,000 |
| 2026-06-10 | Brughera Marco Maria |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
20,000 |
| 2026-06-10 | RALLIS CHRIS A |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
20,000 |
| 2026-06-10 | Cook Jodi A |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Options
|
20,000 |
| 2026-06-01 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
9,747 |